About ruxolitinib e q to
Janus kinase (JAK) inhibitor
Used for
- Certain blood cancers, including myelofibrosis and polycythemia vera
- Graft-versus-host disease after stem-cell transplantation
Usual adult dose
Dose depends on the condition, blood counts, and other medicines; a specialist adjusts it. Follow the prescribed schedule.
Usual dose in children
Specialist-directed dosing may be used for graft-versus-host disease in children; it depends on weight and clinical factors.
Common side effects
- Low blood-cell counts, including anemia and low platelets
- Infections, including shingles
- Bruising or bleeding
- Dizziness or headache
Important warnings
- Can cause serious infections; screening and monitoring may be needed.
- Blood counts and liver tests require monitoring during treatment.
- Do not stop suddenly without the prescriber's direction.
- May increase risks of blood clots, certain cancers, and cardiovascular events.
Pregnancy
May harm an unborn baby; pregnancy should be avoided during treatment and for a period after stopping.
Breastfeeding
Breastfeeding is not recommended during treatment and for a period after stopping.
Interactions
- Strong CYP3A4 inhibitors can raise ruxolitinib levels.
- Fluconazole can increase exposure and may require dose adjustment.
- Rifampin and other strong CYP3A4 inducers can reduce its effect.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.